Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAT-ApMnkQ2
- Development stage
- Preclinical
- Lead developer
- Aptus Biotech
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intperitoneal, Intravenous
01
Overview
CAT-ApMnkQ2 is an RNA aptamer candidate developed by Aptus Biotech for the treatment of anaplastic thyroid cancer (CAT). It is an optimized RNA version of apMNKQ2, a DNA aptamer that targets mitogen-activated protein kinase-interacting serine/threonine-protein kinase 1 (MNK1), specifically the MNK1b isoform. By binding to MNK1, CAT-ApMnkQ2 inhibits the MNK-eIF4E signaling pathway, which is overexpressed in various cancers and plays a critical role in tumor progression, metastasis, and cancer stem cell maintenance. Preclinical studies have demonstrated that targeting this pathway with CAT-ApMnkQ2 induces apoptosis, arrests cell cycle progression, and reduces tumor growth, migration, and invasion, making it a promising therapeutic strategy for highly aggressive and chemotherapy-resistant cancers like anaplastic thyroid cancer.
- Other names
- AptaMnkQ2AptaMnkQ-2AptaMnkQ 2CAT-apMNKQ2CAT-apMNKQ-2CAT-apMNKQ 2
02
Targets
MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)EIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on CAT-ApMnkQ2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAT-ApMnkQ2.